Compare Adaptive Biotechnologies Corp (ADPT) vs D R Horton Inc (DHI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs D R Horton Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while D R Horton Inc trades at $150.18 (market cap $44.16B). The key difference: D R Horton Inc is far larger — about 13.3× Adaptive Biotechnologies Corp's market cap, and D R Horton Inc pays a 1.16% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DHI | |
|---|---|---|
Market Cap | $3.33B | $44.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $184.04 |
52-Week Low | $10.24 | $129.82 |
Enterprise Value | $3.19B | $48.87B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
D.R. Horton (DHI) trades at $155.72, down 1.8% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The stock faces headwinds from declining revenue and profit margins, with 2025 revenue dropping to $34.25B and net income falling to $3.59B. Recent earnings show mixed results with Q3 2025 missing expectations but Q4 2025 and Q1 2026 beating estimates. The company maintains strong operational cash flow of $3.42B despite a net cash outflow of $1.51B in 2025.
DHI presents a cautious opportunity with attractive valuation metrics (P/E 14.73, P/S 1.39) below sector averages, but faces significant housing market challenges. Analyst consensus leans neutral with 44% buy ratings and a $163.13 price target offering 4.8% upside. Key risks include housing market volatility, interest rate sensitivity, and competitive pressures in the homebuilding sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
